Management of Erlotinib-Induced Rash

Introduction to Treatment

The American Society of Clinical Oncology recommends initiating topical antibiotics, such as erythromycin, metronidazole, or nadifloxacin, twice daily for early-stage and low-grade erlotinib-induced rash reactions, and escalating to systemic antibiotics for grade ≥2 reactions, while maintaining aggressive moisturization and gentle skin care throughout treatment 1

For grade 1 (mild) rash, the European Society for Medical Oncology suggests starting topical antibiotic therapy immediately with erythromycin, metronidazole, or nadifloxacin applied twice daily, and using cream or lotion preparations to provide additional moisturization 1, 2
For grade 2-3 (moderate to severe) rash, the National Comprehensive Cancer Network recommends initiating systemic antibiotic treatment in addition to topical therapy, continuing aggressive moisturization with emollients, and considering oral tetracyclines, which have shown effectiveness in randomized controlled trials 1, 2

The American Academy of Dermatology advises applying high SPF sunscreen (SPF 30 or higher) and avoiding sun exposure, using gentle soaps and shampoos exclusively, and maintaining frequent clinical follow-up every 2 weeks minimum, with immediate consultation if flare-up occurs 1, 2

The European Society for Medical Oncology warns against using alcohol-containing gel formulations or topical solutions, as these worsen xerosis that inevitably develops with EGFR inhibitor therapy, and notes that topical corticosteroids are not generally recommended as monotherapy 1, 2
The American Society of Clinical Oncology recommends avoiding topical tazarotene and pimecrolimus, which have been shown ineffective in randomized trials, and advises against discontinuing erlotinib prematurely, as these reactions are effectively treatable at all stages and grades 1, 2

The National Comprehensive Cancer Network notes that the rash differs fundamentally from acne vulgaris because the skin becomes xerotic (dry) rather than seborrheic, making moisturization essential rather than drying agents, and that all dermatologic effects are reversible and heal without sequelae within 4 weeks of treatment discontinuation if necessary 1, 2
The American Academy of Dermatology recommends that treatment should begin as early as possible after onset to prevent progression and maintain quality of life while continuing cancer therapy 1, 2